EyePoint
EyePoint

EyePoint

Pharmaceuticals
WebsiteInvestor RelationsSEC
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

$1.3B

Market Cap • 9/18/2026

2008

(18 years)

Founded

2005

(21 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

8

P/S

476

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,1

EPS

—

Market Cap

Market Cap

1,3B

EV

1,2B

EV/Revenue

418,4

EV/EBITDA

-3,7

EV/EBIT

-3,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-14,5%

Total Yield

-14,5%

Payout

0%

Retained Earnings

-1,3B

Profitability

Gross Margin

41,8%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

9420,2%

Capex/Revenue

142,7%

Capex/D&A

153,1%

Capex/OCF

-1,5%

SBC/OCF

—

% PPE

13,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-41%

CAGR Op. Income 5Y

54%

CAGR Net Income 5Y

49,1%

CAGR EPS 5Y

5,7%

CAGR OCF 5Y

70,4%

Leverage

N.D./EBITDA

0,5

Debt/Equity

0%

Current Ratio

4,5

Quick Ratio

4,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium